(2R)-2-benzyl-3-<<<2-<(methoxyethoxy)methoxy>ethyl>methylamino>carbonyl>propionic acid | 119589-09-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (2R)-2-benzyl-3-<<<2-<(methoxyethoxy)methoxy>ethyl>methylamino>carbonyl>propionic acid
• 英文别名: (2R)-2-benzyl-3-[({2-[(methoxyethoxy)methoxy]ethyl}methylamino)carbonyl]propionic acid；(2R)-2-benzyl-4-[2-(2-methoxyethoxymethoxy)ethyl-methylamino]-4-oxobutanoic acid
• CAS: 119589-09-2
• 化学式: C₁₈H₂₇NO₆
• 分子量: 353.415
• InChiKey: JHKQSTAGRPRFMV-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  25
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  85.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2R)-2-benzyl-3-<<<2-<(methoxyethoxy)methoxy>ethyl>methylamino>carbonyl>propionic acid 、 H-histidine amide of (1'R,2'S,5S)-5-(2'-amino-3'-cyclohexyl-1'-hydroxypropyl)-3-ethyloxazolidin-2-one 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 A-65317
  参考文献：
  名称：

  Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action

  摘要：

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.

  DOI：

  10.1021/jm00169a024
• 作为产物：
  描述：

  benzyl (2R)-2-benzyl-3<<<2-<(methoxyethoxy)methoxy>ethyl>methylamino>carbonyl>propionate 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以100%的产率得到(2R)-2-benzyl-3-<<<2-<(methoxyethoxy)methoxy>ethyl>methylamino>carbonyl>propionic acid
  参考文献：
  名称：

  Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action

  摘要：

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.

  DOI：

  10.1021/jm00169a024

文献信息

• Renin-inhibiting functionalized peptidyl aminodiols and - triols
  申请人：ABBOTT LABORATORIES

  公开号：EP0341602A2

  公开（公告）日：1989-11-15

  A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.

  一个公式为的抑制肾素的化合物： 或其药用可接受的盐、酯或前药。
• Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3-[[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517)
  作者：Saul H. Rosenberg、Kenneth P. Spina、Stephen L. Condon、Jim Polakowski、Zhengli Yao、Peter Kovar、Herman H. Stein、Jerome Cohen、Jennifer L. Barlow

  DOI：10.1021/jm00056a006

  日期：1993.2

  for the design of well-absorbed renin inhibitors, we have followed two strategies to improve potency while maintaining bioavailability. One process involved incorporation of an extended N-terminal residue bearing a weakly basic substituent and is exemplified by compound 25. The other approach centered on the inclusion of an N-terminal sulfonamide and culminated in the discovery of inhibitor 32 (A-72517)

  我们采用了一系列设计良好吸收肾素抑制剂的经验准则，我们遵循了两种策略来提高药效并同时保持生物利用度。一种方法涉及掺入带有弱碱性取代基的延伸的N-末端残基，并以化合物25为例。另一种方法集中于包含N-末端磺酰胺并最终发现抑制剂32（A-72517）。25和32均在大鼠和雪貂中表现出极佳的生物利用度（> 25％），并且在猴子中受到肝脏清除后，在该物种中有效。
• Renin-inhibiting peptidyl heterocycles
  申请人：ABBOTT LABORATORIES

  公开号：EP0307837A2

  公开（公告）日：1989-03-22

  A renin inhibiting compound of the formula: wherein A is a substituent; W is C=O, CHOH or NR₂ wherein R₂ is hydrogen or loweralkyl; U is C=O, CH₂ or NR₂ wherein R₂ is hydrogen or loweralkyl, with the proviso that when W is CHOH then U is CH₂ and with the proviso that U is C=O or CH₂ when W is NR₂; V is CH, C(OH) or C(halogen) with the proviso that V is CH when U is NR₂; R₁ is loweralkyl, cycloalkylalkyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, 4-hydroxybenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (unsubstituted heterocyclic)methyl, (substituted heterocyclic)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino, provided that B is CH₂ or CHOH or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino; R₃ is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, azidoalkyl, aminoalkyl, (alkyl)aminoalkyl, dialkylaminoalkyl, (alkoxy)(alkyl)aminoalkyl, (alkoxy)aminoalkyl, benzyl or heterocyclic ring substituted methyl; R₄ is loweralkyl, cycloalkylmethyl or benzyl; R₅ is OH or NH₂; and Z is a substituent. Also disclosed are compositions for and a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.

  一种式的肾素抑制化合物： 其中 A 是取代基；W 是 C=O、CHOH 或 NR₂，其中 R₂ 是氢或低级烷基；U 是 C=O、CH₂ 或 NR₂，其中 R₂ 是氢或低级烷基，但当 W 是 CHOH 时，U 是 CH₂，当 W 是 NR₂ 时，U 是 C=O 或 CH₂；V 是 CH、C(OH) 或 C(卤素)，但当 U 是 NR₂ 时，V 是 CH；(取代杂环)甲基、苯乙基、1-苄氧基乙基、苯氧基、噻吩氧基或苯胺基，但当 R₁ 为苯氧基、噻吩氧基或苯胺基时，B 为 CH₂ 或 CHOH 或 A 为氢；R₃ 是低级烷基、低级烯基、((烷氧基)烷氧基)烷基、羧基烷基、(硫代烷氧基)烷基、叠氮烷基、氨基烷基、(烷基)氨基烷基、二烷基氨基烷基、(烷氧基)(烷基)氨基烷基、(烷氧基)氨基烷基、苄基或杂环取代的甲基；R₄ 是低级烷基、环烷基甲基或苄基；R₅ 是 OH 或 NH₂；Z 是取代基。 还公开了治疗高血压的组合物和方法、制造肾素抑制化合物的方法以及制造肾素抑制化合物的中间体。
• ROSENBERG, SAUL H.;WOODS, KEITH W.;SHAM, HING L.;KLEINERT, HOLLIS D.;MART+, J. MED. CHEM., 33,(1990) N, C. 1962-1969
  作者：ROSENBERG, SAUL H.、WOODS, KEITH W.、SHAM, HING L.、KLEINERT, HOLLIS D.、MART+

  DOI：——

  日期：——
• US4927807A
  申请人：——

  公开号：US4927807A

  公开（公告）日：1990-05-22